Sapir Cohen Shvefel

Sapir Cohen Shvefel

Auto-generated profile, based on publicly available information

Sapir Cohen Shvefel

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2024 in Cancer Discovery
Verified
Journal Article
Open access
SSSapir Cohen Shvefel
Sapir Cohen Shvefel
JPJoy A. Pai
Joy A. Pai
YCYingying Cao
Yingying Cao
LPLipika R. Pal
Lipika R. Pal
OBOsnat Bartok
Osnat Bartok
YSYardena Samuels
Yardena Samuels
Low intratumor heterogeneity correlates with increased patient survival and immunotherapy response. However, even highly homogeneous tumors are variably aggressive, and the immunologic factors impacting aggressiveness remain understudied. In this study, we analyzed the mechanisms underlying immune escape in murine tumors with low intratumor heterogeneity. We used immunophenotyping and single-cell RNA sequencing to compare the temporal growth of in vivo transplanted, genetically similar, rejected and nonrejected single-cell clones. Nonrejected clones showed high infiltration of tumor-associated macrophages, lower T cell infiltration, and increased T cell exhaustion when compared with rejected clones. Comparative analysis of rejection-associated gene expression programs, combined with in vivo CRISPR knockout screens of candidate regulators, identified macrophage migration inhibitory factor (Mif) as a major contributor to preventing immune rejection. Mif knockout resulted in smaller tumors and reduced tumor-associated macrophage infiltration. These results were validated in patients with melanoma. Overall, our homogeneous tumor system can uncover factors regulating growth variability and identifies Mif as critical in aggressive melanoma. Significance: In this study, we find that Mif expression is associated with tumor growth and aggressiveness, specifically in tumors with low heterogeneity. These findings could facilitate the development of new strategies to treat patients with homogeneous, high MIF–expressing tumors that are unresponsive to immune checkpoint therapy.

17 June 2026
Verified
Other
Open access
SSSapir Cohen Shvefel
Sapir Cohen Shvefel
JPJoy A. Pai
Joy A. Pai
YCYingying Cao
Yingying Cao
LPLipika R. Pal
Lipika R. Pal
OBOsnat Bartok
Osnat Bartok
YSYardena Samuels
Yardena Samuels
List of antibodies used for IHC staining of human samples.

17 June 2026
Verified
Other
Open access
PDF file
SSSapir Cohen Shvefel
Sapir Cohen Shvefel
JPJoy A. Pai
Joy A. Pai
YCYingying Cao
Yingying Cao
LPLipika R. Pal
Lipika R. Pal
OBOsnat Bartok
Osnat Bartok
YSYardena Samuels
Yardena Samuels
Immunopeptidomics and TCR sequencing analyses showed similar results for the rejected and non-rejected SCCs.

17 June 2026
Verified
Other
Open access
PDF file
SSSapir Cohen Shvefel
Sapir Cohen Shvefel
JPJoy A. Pai
Joy A. Pai
YCYingying Cao
Yingying Cao
LPLipika R. Pal
Lipika R. Pal
OBOsnat Bartok
Osnat Bartok
YSYardena Samuels
Yardena Samuels
CyTOF analysis comparing tumors derived from Mif WT and Mif KO validating the scRNAseq findings.

17 June 2026
Verified
Other
Open access
SSSapir Cohen Shvefel
Sapir Cohen Shvefel
JPJoy A. Pai
Joy A. Pai
YCYingying Cao
Yingying Cao
LPLipika R. Pal
Lipika R. Pal
OBOsnat Bartok
Osnat Bartok
YSYardena Samuels
Yardena Samuels
List of antibodies used for CODEX multiplexed tissue imaging

17 June 2026
Verified
Other
Open access
SSSapir Cohen Shvefel
Sapir Cohen Shvefel
JPJoy A. Pai
Joy A. Pai
YCYingying Cao
Yingying Cao
LPLipika R. Pal
Lipika R. Pal
OBOsnat Bartok
Osnat Bartok
YSYardena Samuels
Yardena Samuels
Supplementary Table 2 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma